Explosive Growth Potential Through New Acquisitions
New Premium Alert Avalon GloboCare (NASDAQ: ALBT) Creating A
Biotech Powerhouse, and Pipeline of Potential Acquisitions
This is Kevin Vander with "10XProTrader" delivering you your new premium alert for Monday 9/18 trading session is Avalon GloboCare Corp. (NASDAQ: ALBT).
The market opens in 1 hour.
The Company has several bullish catalysts in the pipeline and is on the verge of disrupting a $127 Billion cellular therapeutics space and has been making major strides with Blockbuster Acquisitions!
Later in this report, I will cover ALBT and detail their explosive growth potential through new acquisitions.
You need to see (firsthand) why I am so excited about ALBT and its heart-pounding potential for your portfolio.
Not only are their technicals bullish, but there are also several significant catalysts in play right now that could be key factors for a potential breakout.
CATALYST #1 -- Key Driver For Exceptional Shareholder Growth Avalon Executes NEW Merger & Acquisitions Roll-Up Strategy
A potential catalyst that provides a very bullish outlook is ALBT's new commercial strategy focused on laboratory acquisitions and diagnostics.
Avalon said, their goal is to take advantage of a unique roll-up oppo∙rtunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with strong financial track records and niche-market advantages.
Avalon is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Their evolving strategy involves acquiring ownership or license rights to precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, share ownership structures or distribution rights. They intend to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.
CATALYST #2 -- Explosive Growth Potential Through New Acquisitions
Avalon Acquired Laboratory Services MSO (LSM) Creating A Biotech Powerhouse, and Pipeline of Potential Acquisitions
A potential catalyst that provides a very bullish outlook is ALBT has executed on their new commercial strategy focused on laboratory acquisitions and diagnostics, with the acquisition of Laboratory Services MSO (LSM).
As a first major step into the laboratory market, they acquired a 40% interest in Laboratory Services MSO (LSM). LSM generated revenue of $14.7Mln and net income of $6.3Mln in 2022. In turn, they believe their pr∙ofit-sharing arrangement with LSM will result in significant future ca∙sh flow for Avalon.
Since the acquisition, LSM has executed on its growth plan and has expanded their service offering to customers seeking to utilize providers within their insurance network. In addition, they have continued to evaluate additional accretive acquisitions, which they just announced on Sep. 13, 2023 they have made two significant accretive acquisitions.
Avalon GloboCare Corp (NASDAQ: ALBT) just announced that its 40%-owned clinical diagnostics and reference lab Laboratory Services MSO (LSM) has made two significant accretive acquisitions:
Merlin Medical Supply ("MMS") is a profitable, well-established Home Medical Equipment ("HME") and Durable Medical Equipment ("DME") company providing acute and non-acute medical supplies in Ventura County, California, which has contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health and Gold Coast.
Additionally, they also acquired Leading Edge Innovations which owns a proprietary, patented FDA-registered, in-market, male catheter device, approved for reimbursement by Medicare and a number of high-profile private insurance providers.
CATALYST #3 -- Avalon GloboCare Corp. (NASDAQ: ALBT) Expands
its R&D Pipeline and Intellectual Property Portfolio
Another potential catalyst that provides a very bullish outlook. ALBT is seizing its oppo∙rtunities to expand its R&D pipeline and intellectual property portfolio.
A Clinical Breakthrough For Fusion Gene Map Technologies
They recently strengthened that proposition. Avalon announced that it has deployed a breakthrough fusion gene map technology to develop companion diagnostic kits and devices to enhance the personalized clinical management of leukemia patients. Specifically, in collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established, with the results previously published in the Blood Cancer Journal.
Notably, these fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology called "Whole Transcriptome Sequencing," multiple previously unknown fusion genes were identified that could potentially establish novel diagnostic and therapeutic targets. Avalon is applying the bioinformatics from the fusion gene map to accelerate the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
Furthermore, because the fusion gene map technology provides an unprecedented oppo∙rtunity to identify and validate fusion gene products as potential novel therapeutic targets, interest from the over 20 ongoing clinical studies to treat forms of leukemia, including those by Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), could strengthen. Interest from big pharma would be in addition to ALBT seizing its oppo∙rtunities to expand its R&D pipeline and intellectual property portfolio.
CATALYST #4 -- Key 'Patent Wins' Avalon GloboCare Adds
The "QTY Code" "Patent" to portfolio!
Another potential catalyst that provides a very bullish outlook is ALBT has received a new patent to add to their portfolio.
ALBT announced a "key patent filed" with one of the most prestigious universities in the world – Massachusetts Institute of Technology (MIT)!
The Freehold, New Jersey-based company announced the United States Patent and Trademark Office (USPTO) issued a Notice of Publication for U.S. Patent No. 11,555,060, titled "QTY Fc Fusion Water Soluble Receptor Proteins."
The "QTY Code" is a Breakthrough Technology!
This patented technology could be a huge upside driver for ALBT as they grow their lab testing services.
This patent, a collaborative effort with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT), encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code."
The code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.
"Our patented technology can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications," CEO David Jin explained.
"The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications, including, among others, mitigation of the 'cytokine storm' associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies."
Avalon GloboCare is a trailblazing innovator in precision diagnostics and clinical laboratory services.
CATALYST #5 -- Avalon GloboCare Corp (NASDAQ: ALBT) Expands
IP Portfolio And Files 16 New Patent Applications
Another potential catalyst that provides a very bullish outlook is ALBT expands IP portfolio and files 16 new patent applications.
Avalon GloboCare Corp (NASDAQ: ALBT) jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.
The new intellectual property covers three core patent families:
Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon's AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the "cytokine storm" associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a "molecular GPS system" to guide the trafficking and delivery of a payload to a targeted destination in the body.
"These latest patent applications solidify and expand our robust IP portfolio, both in the U.S. and internationally," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "We are especially honored to partner with several leading global academic researchers and institutions in the field of cell therapy, as co-inventors of the technologies. We believe these patent applications will extend our geographic IP protection and are timed to maximize the duration of the patents for decades to come. These patents are within our core competencies in the areas of CAR-T, QTY protein design and S-layer technologies, thereby enhancing our position as a leader in immuno-oncology and cellular medicines. Collectively, we believe each of these patents covers therapies and technologies that target large, addressable markets. They are all supported by strong preclinical data as we rapidly advance towards first-in-human clinical trials."
CATALYST #6 -- ALBT is a Game-Changing First Mover
with its FDA registered product
ALBT is a game-changing first mover with its FDA registered product. The KetoAir™ breathalyzer medical device is registered with the United States FDA as Class I medical device (US FDA registration # 3026284320).
KetoAir™ is the first breathalyzer on the market that uses an artificial intelligence (AI) nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management.
This could be a huge upside driver for ALBT, as they secured exclusive distribution rights and are making rapid progress towards commercialization of the KetoAir™ breathalyzer device.
Turn Your Complete Attention to Avalon GloboCare (NASDAQ: ALBT)
New Premium Nasdaq Biotech Breakout Alert for Monday!
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
CATALYST #7 -- Transforming Milestones Into Catalysts
Revolutionary key clinical-stage milestones that could send the shares of ALBT shares vertical.
It's very rare to see a low priced NASDAQ Biotech stock achieve as many clinical-stage milestones as this incredible little gem.
AVA-001: Avalon have successfully completed the first-in-human clinical trial of our AVA-001 anti-CD19 CAR-T cell therapy as a bridge to allogeneic bone marrow transplantation for patients with relapsed/refractory B-ALL at the Lu Daopei Hospital (registered clinical trial number NCT03952923) with excellent efficacy (90% complete remission rate) and minimal adverse side effects. We are currently expanding the indication and plan to recruit patients in the USA for AVA-001 to include both relapsed/refractory B-ALL and non-Hodgkin lymphoma patients.
AVA-011 and FLASH-CAR™: Avalon advanced its next generation immune cell therapy using mRNA-based, non-viral FLASH-CAR™ technology co-developed with our strategic partner Arbele Limited. The adaptable FLASH-CAR™ platform can be used to create personalized cell therapy from a patient's own cells, as well as off-the-shelf cell therapy from a universal donor. Our leading candidate, AVA-011, is currently at the process development stage to generate clinical-grade cell-therapy products for subsequent clinical studies.
AVA-Trap™: Avalon's AVA-Trap™ therapeutic program plans to enter animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms. We initiated a sponsored research and co-development project with Massachusetts Institute of Technology (MIT) led by Professor Shuguang Zhang as Principal Investigator in May 2019. Using the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective cytokines. AVA-TrapTM can potentially generate novel therapeutic targets for cellular therapy, as well as in the field of precision diagnostics. We do not have a timeline for the next steps of this study.
Avalon's Top Earning Drivers: The Revenue Powerhouse!
Qualitative Drug Screening: We use fast, accurate, and efficient equipment to provide practitioners with the tools to quickly determine if a patient is following their designated treatment plan. In most instances, we are able to provide a practitioner with qualitative drug class results the same day the sample is received.
Drug Testing by LCMS: We use top-of-the-line instrumentation to test for an extensive list of drugs to assist practitioners in ensuring patient treatment plan compliance. We are able to tell our practitioner clients what substances are in the patient's system and how much is present within 48 hours of sample receipt.
Chemistry Wellness: We provide an extensive chemistry test menu that gives physicians the information to better treat their patients and maintain their overall wellness. The panels that we test for are thyroid panel, comprehensive metabolic panel, kidney profile, liver function tests, and other individual tests.
PCR COVID-19 Testing: Our lab offers highly complex and advanced PCR instrumentation to provide accurate, fast, and easy-to-understand results that tell physicians if their patients have been infected with the SARS-CoV-2 virus that causes COVID-19.
Urine Wellness Testing: Using Real-Time PCR, we are able to provide our physician clients with a comprehensive wellness test from a urine sample. The testing provides the physician with valuable information from an Anatomic Pathology Screen as well as a comprehensive STD/STI screen and a UTI test that includes antibiotic resistance.
(PGx) Testing: A PGx test uses real-time PCR to find genetic variants that affect how a person metabolizes various medications using DNA collected from a patient using a mouth swab. The testing can be used by clinicians to diagnose the cause of medication side effects, determine safe and appropriate dosing, reduce medication side effects, increase the effectiveness of medications, and avoid frustrating side effects.
Avalon Uncovered: 7 Investor Highlights That
Everyone Needs to Know
Avalon Has an Extremely Low Float Producing Very High Volatile Swings In Price Movement
Avalon Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)
Avalon Subsidiary Launches New Laboratory Test For Tuberculosis
Avalon Laboratory Services MSO Announces Expansion into Arizona
Avalon Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
Avalon Reports Strong financial Results Laboratory Services MSO Revenue of $14.7Mln and Net Income of $6.3Mln in 2022
Avalon Has Recently Bounced Off Its Support Level of $1.00/share Twice In The Last 30 Days for 30% Short=Term Gains
Why Should You Pay Close Attention to (NASDAQ: ALBT)?
Because... 10XProTrader consistently produces real-time gains like you see right below.
>>>> Interested In Potential Gains Like These Below <<<<
• (NAOV): Open at $2.10 8/30 – High $4.23 8/3/20 (101% Gains)
• (PRFX): Pre-Mkt at $5.37 7/3 – High $26.41 7/11 (391% Gains)
• (LIXT): Pre-Mkt at $5.26 7/17 – High $9.50 7/11 (80% Gains)
• (PWM): Pre-Mkt at $10.00 7/7 – High $31.88 7/11 (218% Gains)
• (DERM): Pre-Mkt at $1.50 7/3 – High $3.19 7/10 (112% Gains)
• (CRBU): Pre-Mkt at $4.13 7/6 – High $7.78 7/10 (88% Gains)
• (GRRR): Pre-Mkt at $3.25 7/7 – High $6.98 7/10 (114% Gains)
• (MOB): Pre-Mkt at $1.57 7/10 – High $3.33 (112% Gains)
Every single stock symbol you see above is a real-time alert that I released to my 10X community. These are NOT fake alerts!
Conclusion: With Avalon expanding its "R&D Pipeline" and "intellectual property Portfolio" produces a strong catalyst for incredible upside potential!
CATALYST: ALBT Executes NEW "Merger & Acquisitions" "Roll-Up Strategy"
Creating A Biotech Powerhouse, and Pipeline of Potential Acquisitions!
You need to add ALBT to the top of your watch list (first thing) this morning.
I am urging all of my members to add (NASDAQ: ALBT) to the top of their watch list right now, and be ready at the opening bell this morning! I'm looking for another potential double-digit win∙ner.
Post a Comment
Post a Comment